Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by Rabin Medical Center.
Recruitment status was  Not yet recruiting
Ferring Pharmaceuticals
Information provided by:
Rabin Medical Center Identifier:
First received: June 9, 2009
Last updated: June 11, 2009
Last verified: June 2009

The objective of the study is to confirm that the efficacy of vaginal progesterone is at least as good as oral progesterone in order to protect the endometrium of uncontrolled proliferation and prevent endometrial cancer.

Condition Intervention Phase
Endometrial Hyperplasia
Endometrial Cancer
Drug: progesterone
Drug: activella
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy & Tolerability of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Replacement Therapy - Phase II Comparative Study

Resource links provided by NLM:

Further study details as provided by Rabin Medical Center:

Primary Outcome Measures:
  • Comparing the proportion of women with endometrial thickness not exceeding 8mm and change not exceeding 3mm between the two groups. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Comparison of the proportion of bleeding pattern between the two groups. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • To demonstrate that vaginal progesterone tablets decrease systemic progesterone adverse reactions using a questionnaire. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 60
Study Start Date: June 2009
Estimated Study Completion Date: November 2010
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Progesterone vaginal tablet
Group A - Daily use of Endometrin 100 mg progesterone vaginal tablet, and Estrofem orally.
Drug: progesterone
Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
Other Name: Endometrin
Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
Drug: activella
Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally

Detailed Description:

Estrogen Replacement Therapy must be opposed by progesterone in order to protect the endometrium of uncontrolled proliferation and prevent endometrial cancer, in women with an intact uterus.


Ages Eligible for Study:   45 Years to 60 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women who are candidates for Hormone Replacement Therapy due to menopausal symptoms.
  • Women with an intact uterus.
  • No menses within the 12 months preceding screening visit and /or FSH >30 IU/L.
  • Endometrial thickness ≤ 5 mm.

Exclusion Criteria:

  • Submucosal fibroid/s that applying pressure and affecting endometrial thickness
  • Other medication that could affect estrogenic state.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00919919

Contact: Aviva Kaplan 972-3-9377534

Rabin Medical Center Beilinson Hospital Not yet recruiting
Petach Tikva, Israel
Contact: Aviva kaplan    972-50-5511591      
Principal Investigator: Boris kaplan, prof         
Sub-Investigator: Michael Hirsh, Dr'         
Sub-Investigator: Ravit Nahum, Dr'         
Sub-Investigator: Dove Lazarovitz, Dr'         
Sub-Investigator: Avi Ninio, Dr'         
Sub-Investigator: Yosi Maai, Dr'         
Sub-Investigator: Dan Kelman, Dr'         
Sub-Investigator: Raia Nir, Dr'         
Sub-Investigator: Ruth Bloch, Dr'         
Sub-Investigator: Yehuda Yeger, Dr'         
Sub-Investigator: Reuven Amster, Dr'         
Sub-Investigator: Tzvi Zehavi, Dr'         
Sub-Investigator: Gay Gutman, Dr'         
Sub-Investigator: Yosi Menkas, Dr'         
Sponsors and Collaborators
Rabin Medical Center
Ferring Pharmaceuticals
Principal Investigator: Boris Kaplan, prof Rabin Medical Center Beilinson Hospital
  More Information

No publications provided

Responsible Party: Prof. Boris Kaplan, Gynecology Department Identifier: NCT00919919     History of Changes
Other Study ID Numbers: fr003, 5340/09
Study First Received: June 9, 2009
Last Updated: June 11, 2009
Health Authority: Israel: Ministry of Health

Keywords provided by Rabin Medical Center:
Endometrial Thickness

Additional relevant MeSH terms:
Endometrial Hyperplasia
Genital Diseases, Female
Pathologic Processes
Uterine Diseases
Norethindrone acetate
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on November 24, 2014